<DOC>
	<DOCNO>NCT02082119</DOCNO>
	<brief_summary>To evaluate safety feasibility hypofractionated IMRT addition chemotherapy , concomitant adjuvant , patient newly diagnose HGGs surgery . Primary endpoint : progression free survival ( PFS ) , Overall Survival ( OS ) Toxicity . Secondary endpoint : evaluate Quality life ( QoL ) patient surgery , concomitant chemoradiotherapy adjuvant chemotherapy neuropsychological examination .</brief_summary>
	<brief_title>Hypofractionated IMRT With Temozolomide HGG</brief_title>
	<detailed_description>We design study hypofractionated intensity modulate radiation therapy ( IMRT ) , use VMAT RapidArc approach . The potential advantage approach deliver selective irradiation tumor 's target reduce dose normal brain allow deliver high dose , optimize therapeutic window</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>Age 18 70 year Karnosky performance status ( KPS ) ≥60 Patients age &gt; 70 year KPS ≥80 Histopathologically confirm HGG Estimated survival ≥ 3 month . Multifocal tumor Normal liver , Kidney bone marrow function Written inform consent Prior radiation therapy KPS ≤ 60 Age &gt; 70 year KPS &lt; 70 Other primary cancer Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>